Synthetic Biologics, Inc.
(NYSE Amex Equities : SYN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -3.29%195.800.0%$1633.73m
BIIBBiogen, Inc. 0.50%385.441.7%$1248.99m
SNSSSunesis Pharmaceuticals, Inc. 5.98%12.760.7%$891.97m
NVAXNovavax, Inc. -4.44%171.9079.8%$659.95m
AMGNAmgen, Inc. -1.18%237.931.3%$618.82m
BNTXBioNTech SE -0.13%213.920.0%$524.59m
VRTXVertex Pharmaceuticals, Inc. -0.63%187.181.9%$494.23m
GILDGilead Sciences, Inc. -1.39%66.281.0%$473.61m
REGNRegeneron Pharmaceuticals, Inc. -0.07%535.662.7%$374.79m
ILMNIllumina, Inc. -0.19%454.473.5%$358.27m
ALXNAlexion Pharmaceuticals, Inc. -0.36%179.332.0%$336.10m
OCGNOcugen, Inc. -2.61%6.370.0%$279.93m
EXASEXACT Sciences Corp. -1.42%125.1018.1%$188.05m
IOVAIovance Biotherapeutics, Inc. -1.46%24.260.0%$167.66m
TXG10X Genomics, Inc. -2.07%194.670.0%$167.62m

Company Profile

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.